1 **Dynamics of T-cell responses following COVID-19 mRNA vaccination**

2 **and breakthrough infection in older adults**

ABSTRACT (248/250 words)

- HLA-A*02:03 and higher post-vaccination CD8+ T-cell frequencies, which may be
- attributable to numerous strong-binding HLA-A*02:03-specific CD8+ T-cell epitopes in
- spike.
-
- **Conclusion**: Older adults mount robust T-cell responses to two- and three-dose COVID-
- 19 mRNA vaccination, which are further boosted following breakthrough infection.

72 **INTRODUCTION**

73 In many jurisdictions, older adults were prioritized to receive COVID-19 vaccines 74 and boosters due to their increased risk of severe outcomes following SARS-CoV-2 75 infection¹⁻³. While vaccination has been highly effective at preventing severe disease in 76 this group⁴, vaccine responses in older adults can nevertheless be blunted by age-related 77 immune impairments, or elevated frequencies of chronic health conditions that can 78 dampen adaptive immune responses⁵⁻⁹. Indeed, after COVID-19 vaccines were rolled out 79 globally, observational studies revealed that older adults generally mounted weaker 80 binding and neutralizing antibody to the primary vaccine series¹⁰⁻¹⁵, leading to 81 widespread recommendations that this group receive third vaccine doses and regular 82 booster vaccinations^{16,17}. Comparably fewer studies however have investigated cellular 83 immune responses to COVID-19 vaccination − namely, CD4+ helper T cells that play a 84 central role in the generation of antigen-specific B cells and antibody responses, and CD8+ cytotoxic T cells that recognize and eliminate virus-infected cells¹⁸ $-$ in older 86 compared to younger adults. While mRNA vaccines can induce strong T cell 87 responses^{19,20}, evidence suggests that the frequency of spike-specific CD4+ T cells 68 following COVID-19 vaccination may be lower in older adults^{11,13,21}. An improved 89 understanding of age-associated differences in T cell responses to COVID-19 mRNA 90 vaccines will help to inform future efforts to enhance protective immunity in older adults. 91 Here, we investigated the dynamics of spike-specific CD4+ and CD8+ T cell responses 92 elicited after two and three doses of COVID-19 mRNA vaccine in a cohort of 40 older 93 adults and 50 younger healthcare workers who remained naive to SARS-CoV-2 during 94 this time. We additionally investigated spike-specific $CD4+$ and $CD8+$ T cell responses

Diagnostics), combined with diagnostic (PCR- and/or rapid-antigen-test-based)

- information where available.
-

- NucliSENS EasyMag system (BioMerieux). HLA class I genotyping was performed by
- locus-specific Polymerase Chain Reaction (PCR) amplification of the region spanning
- 143 exons 2 and 3 of the HLA-A, B and -C loci, as reported previously²³. Amplicons were bi-
- directionally sequenced on an ABI 3730xl automated Sanger DNA sequencer using
- BigDye (v3.1) chemistry (Applied Biosystems). Chromatograms were analyzed using the
- 146 semiautomatic base-calling software $RECall²⁴$, with the resulting bulk sequences
- interpreted to subtype-level resolution using in-house software.
-

Epitope prediction. Peptides derived from ancestral spike protein (GenBank:

150 NC 045512.2) that are likely to bind to HLA-A*02:01 and/or A*02:03 were predicted

151 using NetMHCpan-4.1 (https://services.healthtech.dtu.dk/services/NetMHCpan-4.1; ²⁵).

Potential 8-, 9-, and 10- amino acid epitopes were determined for both alleles using

- default thresholds for strong binders (% Rank <0.5) and weak binders (% Rank 0.5-2).
-

 Statistical analyses. Continuous variables were compared using the Mann-Whitney U- test (for unpaired data) or Wilcoxon test (for paired measures). Relationships between continuous variables were assessed using Spearman's correlation. Zero-inflated beta regressions were used to investigate the relationship between age and vaccine-induced T- cell responses using a confounder model that adjusted for variables that could influence these responses, or that differed in prevalence between groups. These regressions model the response variable as a beta-distributed random variable whose mean is given by a linear combination of the predictor variables (after a logit transformation). Beta

Participant characteristics

 Characteristics of the 40 older adults (OA) and 50 younger health care workers (HCW), all of whom remained COVID-19 naive until at least one month after their third vaccine dose, are shown in **Table 1**. OA and HCW were a median of 79 and 39 years old, respectively (overall range 24-93 years old), and predominantly female. OA were

reaching a median 0.25% (IQR 0.14-0.57%) in OA and a median 0.42% (IQR 0.14-

0.66%) in HCW, a difference that was not statistically significant between groups

(p=0.28; **Figure 1A**). A third vaccine dose further boosted the percentage of spike-

 specific CD4+ T-cells (paired measures p<0.0001 for both OA and HCW), reaching a median 0.62% (IQR 0.27-0.91) in OA compared to a median 0.77% (IQR 0.45-1.08) in HCW, a difference that was not statistically significant between groups (p=0.07) (**Figure 1A**). CD8+ T cell responses also increased significantly from pre-vaccine levels following two vaccine doses (paired measures p=0.002 in both groups), reaching a median 0.24% (IQR 0.13-0.45%) in OA and a median 0.33% (IQR 0.16-0.63%) in HCW, a difference that was not statistically significant between groups (p=0.11; **Figure 1B**). A 217 third vaccine dose further boosted the percentage of spike-specific CD8+ T-cells (paired measures p<0.0001 for both groups) to a median 0.62% (IQR 0.34-1.08%) in OA and a median 0.78% (IQR 0.42-1.18%) in HCW, a difference that was not statistically significant between groups (p=0.39; **Figure 1B**). We observed no correlation between age and the percentage of spike-specific CD4+ or CD8+ T-cells after either the second or third vaccine dose, when age was 223 assessed as a continuous variable (Spearman's ρ ranged from = -0.14 to -0.03; all $p > 0.20$; not shown). Moreover, we confirmed that age remained not significantly associated with vaccine-induced T-cell responses after adjusting for relevant sociodemographic, health and vaccine-related variables (**Tables S1 and S2**). Rather, the strongest predictor of the 227 % of spike-specific CD4+ and CD8+ T-cells following three vaccine doses was the corresponding % of spike-specific T-cells following two doses (**Table S2**). For example, the zero-inflated beta regression estimates for the impact of each 1% increment in post- second dose T-cell frequencies on post-third dose frequencies was 0.69 for CD4+ T-cells 231 ($p=2\times10^{-16}$) and 0.77 for CD8+ T-cells ($p=1\times10^{-13}$) (**Table S2**). To interpret these

 The percentage of spike-specific CD4+ and CD8+ T cells correlated strongly with 249 one another after the second vaccine dose (Spearman's $p=0.60$; $p<0.0001$) as well as after the third dose (Spearman's ρ=0.59; p<0.0001; **Figure 2A**). No correlation however was observed between the magnitude of the COVID-19 vaccine antibody response, in terms of serum anti-spike Receptor Binding Domain (RBD) IgG concentrations after either the second or third vaccine dose, and the percentage of spike-specific CD4+ T-cells at those

254 times (Spearman's $\rho = -0.09$, p=0.41 for post-second dose; $\rho = -0.11$, p=0.32 for post-

third dose; **Figure 2B**).

Correlations between HLA class I genotypes and CD8+ T-cell responses

 Participants expressed a total of 29 different HLA-A, 42 HLA-B and 23 HLA-C alleles, defined at the subtype level (**Figure S2).** Exploratory analyses that included all HLA alleles observed in a minimum of 5 participants revealed that, following three vaccine doses, expression of HLA-A*02:03 was associated with higher spike-specific 262 CD8+ T cell response frequencies after correcting for multiple comparisons $(p=0.01;$ 263 q=0.08), while expression of B*39:01, B*44:03, or $C*07:01$ was associated with lower spike-specific CD8+ T cell response frequencies (all p<0.03, q<0.13) (**Table S3**). After correcting for multiple comparisons, we did not identify any HLA class I alleles that were significantly associated with spike-specific CD8+ T cell response frequencies after *two* 267 vaccine doses, but the top allele after two vaccine doses was also $A*02:03$ (p=0.02; q=0.34; not shown). 269 To further explore the interaction with $A*02:03$, we used NetMHCpan-4.1²⁵ to identify all 8-, 9-, and 10-amino acid spike epitopes that are predicted to bind to this allele or to the common and closely related A*02:01 allele, which showed no beneficial impact on CD8+ T cell responses after three vaccine doses (p=0.46, q=0.56; **Table S3**). In total, 29 strong binders (% Rank <0.5) and 56 weak binders (% Rank 0.5-2) were

observed for A*02:03, compared to 20 strong binders and 58 weak binders for A*02:01

(**Table S4**). A cumulative view of strong binders, plotted by % Rank, is shown in **Figure**

3A. An analysis of 30 shared epitopes that displayed strong binding affinity for either

 COVID-19 mRNA vaccine, and that these responses were enhanced similarly by a third vaccine dose regardless of age. Furthermore, both older and younger adults mounted robust T cell responses following a post-vaccine breakthrough infection. These results are consistent with a recent report showing that spike-specific T cell responses measured using an AIM assay were equivalent in older and younger adults after two doses of mRNA vaccine²¹, though another study reported impaired T cell effector function, 306 including lower cytokine production, in older adults following two vaccine doses¹³. Prior studies have also found weaker T cell responses in older adults after only one vaccine dose^{11,21,28}, but we did not examine this time point here. We also observed no association between CD4+ T cell responses and RBD-specific IgG antibodies after either two or three vaccine doses, suggesting that sufficient T cell help was provided to stimulate spike-specific B cell responses despite a wide range of antigen-specific CD4+ T cell frequencies. While our results do not completely rule out the possibility of age-related dysfunction in vaccine-induced T cells among older adults, our data suggest that the impact of any age-associated T cell impairment is likely to be modest after the second and third vaccine dose.

 Our data also indicate that HLA class I alleles modulate the frequency of spike- specific CD8+ T cell responses following vaccination. Notably, participants expressing HLA-A*02:03 exhibited higher CD8+ T cell responses, while individuals expressing B*39:01, B*44:03, or C*07:01 exhibited lower responses (though these associations only reached statistical significance after three vaccine doses). Bioinformatics analyses predicted a higher number of spike peptides that bound with high affinity to HLA-A*02:03 compared to the closely related A*02:01 allele (which was not associated with a

- to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for
- Health Research (GA2-177713 and the Coronavirus Variants Rapid Response Network
- (FRN-175622) to MAB), the Canada Foundation for Innovation through Exceptional
- Opportunities Fund COVID-19 awards (to MAB, MLD, ZLB). FM holds a fellowship
- from the CIHR Canadian HIV Trials Network. FY and EB were supported by an SFU
- Undergraduate Research Award. MLD and ZLB hold Scholar Awards from the Michael
- Smith Foundation for Health Research.

Table 1: Participant characteristics

376 Sociodemographic, health, and vaccine data were collected by self-report and confirmed

377 through medical records where available.

^b 378 Chronic conditions were defined as hypertension, diabetes, asthma, obesity, chronic diseases

379 of lung, liver, kidney, heart or blood, cancer, and immunosuppression due to chronic

380 conditions or medication.

381 All SARS-CoV-2 infections occurred between one and six months after the third vaccine

382 dose.

FIGURE LEGENDS

Figure 1. SARS-CoV-2 spike-specific T-cell frequencies before and after COVID-19

- **mRNA vaccination.** *Panel A:* Spike-specific CD4+ T-cell frequencies before and after
- two and three-dose COVID-19 vaccination. Older Adults (OA) are in orange; younger
- Health Care Workers (HCW) are in blue. All participants are COVID-19 naive. Red bars
- indicate median and IQR. The Mann-Whitney U-test was used for between-group
- comparisons and the Wilcoxon matched pairs test was used for longitudinal paired
- comparisons. P-values are not corrected for multiple comparisons. *Panel B:* Same as
- panel A, but for spike-specific CD8+ T-cell frequencies.
-

Figure 2. Correlations between cellular and humoral immune measures after two

and three-dose COVID-19 mRNA vaccination. *Panel A:* Correlation between spike-

- specific CD4+ and CD8+ T-cell frequencies one month after the second dose (open
- circles) and one month after the third dose (closed circles) in the combined cohort. *Panel*
- *B*: Correlation between spike-specific CD4+ T-cell frequencies and spike-specific IgG
- binding antibodies, measured in one month after the second dose (open circles) and one
- month after the third dose (closed circles) in the combined cohort. All participants are
- COVID-19 naive.
-

Figure 3. Comparison of HLA-A*02:01 and A*02:03 predicted strong-binding

- **epitopes in SARS-CoV-2 spike.** *Panel A:* Cumulative frequencies of predicted strong-
- binding epitopes in SARS-CoV-2 spike restricted by HLA-A*02:01 (blue line) and
- 406 $A*02:03$. Epitope predictions were performed using NetMHCpan4.1²⁵, which defines

-
-
-

REFERENCES

- 29. Bose T, Pant N, Pinna NK, Bhar S, Dutta A, Mande SS. Does immune recognition of SARS-CoV2 epitopes vary between different ethnic groups? *Virus Res* 2021; **305**: 198579.
- 30. Rao V, Chandra N. In-silico study of influence of HLA heterogeneity on CTL responses across ethnicities to SARS-CoV-2. *Hum Immunol* 2022; **83**(12): 797-802.
- 31. Bertinetto FE, Magistroni P, Mazzola GA, et al. The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms. *HLA* 2023.
- 32. Srivastava A, Hollenbach JA. The immunogenetics of COVID-19. *Immunogenetics* 2023; **75**(3): 309-20.
- 33. Sacco K, Castagnoli R, Vakkilainen S, et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. *Nat Med* 2022; **28**(5): 1050-62.
- 34. Smith M, Abdesselem HB, Mullins M, et al. Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. *Viruses* 2021; **13**(5).
- 35. Martin CA, Nazareth J, Jarkhi A, et al. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. *EClinicalMedicine* 2023; **58**: 101926.

Figure 3

